Top

Clinical and Translational Oncology

Published in:

01-08-2018 | Research Article

Deep sequencing reveals the molecular pathology characteristics between primary uterine leiomyoma and pulmonary benign metastasizing leiomyoma

Authors: J. Jiang, M. He, X. Hu, C. Ni, L. Yang

Published in: Clinical and Translational Oncology | Issue 8/2018

Abstract

Purpose

Pulmonary benign metastasizing leiomyoma (PBML), a rare condition of smooth muscle tumor, originates from women with a history of uterine leiomyoma (LM). Numerous genetic studies of uterine LM have been reported; however, there are few cytogenetic and molecular descriptions of PBML. Therefore, molecular subtyping is necessary to understand the pathogenesis of metastasizing sites.

Methods

Driver gene exon-capture sequencing was performed on one patient’s peripheral blood, paraffin samples from primary uterine LM, and lung metastasizing leiomyoma 8 years later.

Results

The results showed that the same missense mutations of BLMH, LRP2, MED12, SMAD2, and UGT1A8 were concurrently mutated in the primary uterine LM and the PBML. Moreover, a splice mutation of PTEN (c.492+1G>A) was uniquely identified in the lung metastasis of the patient.

Conclusion

This study indicates that the metastatic lung lesions were derived from the same malignant cell clone of uterine LMs and later acquired the novel driver mutations in the evolution of the tumor. In addition, driver gene sequencing can discriminate somatic driver mutations as biological indicators of potential malignant leiomyoma and can identify pathogenic variation driver mutations, which could be used for individualized therapy.

Available only for authorised users

Steiner PE. Metastasizing fibroleiomyoma of the uterus: report of a case and review of the literature. Am J Pathol. 1939;15(1):89–110.7.PubMedPubMedCentral

Chen S, Liu RM, Li T. Pulmonary benign metastasizing leiomyoma: a case report and literature review. J Thorac Dis. 2014;6(6):E92–8. https://doi.org/10.3978/j.issn.2072-1439.2014.04.37.PubMedPubMedCentralCrossRef

Ras R, Ksiazek M, Barnas E, Skret-Magierlo J, Kaziolka W, Fudali L, et al. Benign metastasizing leiomyoma in triple location: lungs, parametria and appendix. Przeglad Menopauzalny Menopause Rev. 2016;15(2):117–21. https://doi.org/10.5114/pm.2016.61195.CrossRef

Patton KT, Cheng L, Papavero V, Blum MG, Yeldandi AV, Adley BP, et al. Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Mod Pathol Off J US Can Acad Pathol Inc. 2006;19(1):130–40. https://doi.org/10.1038/modpathol.3800504.CrossRef

Bowen JM, Cates JM, Kash S, Itani D, Gonzalez A, Huang D, et al. Genomic imbalances in benign metastasizing leiomyoma: characterization by conventional karyotypic, fluorescence in situ hybridization, and whole genome SNP array analysis. Cancer Genet. 2012;205(5):249–54. https://doi.org/10.1016/j.cancergen.2012.04.005.CrossRefPubMedPubMedCentral

Cho KR, Woodruff JD, Epstein JI. Leiomyoma of the uterus with multiple extrauterine smooth muscle tumors: a case report suggesting multifocal origin. Hum Pathol. 1989;20(1):80–3.CrossRefPubMed

Sprio RH, McPeak CJ. On the so-called metastasizing leiomyoma. Cancer. 1966;19(4):544–8.CrossRefPubMed

Awonuga AO, Shavell VI, Imudia AN, Rotas M, Diamond MP, Puscheck EE. Pathogenesis of benign metastasizing leiomyoma: a review. Obstet Gynecol Surv. 2010;65(3):189–95. https://doi.org/10.1097/OGX.0b013e3181d60f93.CrossRefPubMed

Abell MR, Littler ER. Benign metastasizing uterine leiomyoma. Multiple lymph nodal metastases. Cancer. 1975;36(6):2206–13.CrossRefPubMed

10.

Yang L, Wang G, Zhao X, Ye S, Shen P, Wang W, et al. A novel WRN frameshift mutation identified by multiplex genetic testing in a family with multiple cases of cancer. PLoS One. 2015;10(8):e0133020. https://doi.org/10.1371/journal.pone.0133020.CrossRefPubMedPubMedCentral

11.

Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213–9. https://doi.org/10.1038/nbt.2514.CrossRefPubMedPubMedCentral

12.

Lin J, Song X, Liu C. Pelvic intravascular leiomyomatosis associated with benign pulmonary metastasizing leiomyoma: clinicopathologic, clonality, and copy number variance analysis. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2014;33(2):140–5. https://doi.org/10.1097/PGP.0b013e31828def26.CrossRef

13.

Tatebe S, Oka K, Kuraoka S, Yatabe Y. Benign metastasizing leiomyoma of the lung: potential role of low-grade malignancy. Thorac Cardiovasc Surg. 2009;57(3):180–3. https://doi.org/10.1055/s-2008-1038637.CrossRefPubMed

14.

Gal AA, Brooks JS, Pietra GG. Leiomyomatous neoplasms of the lung: a clinical, histologic, and immunohistochemical study. Mod Pathol Off J US Can Acad Pathol Inc. 1989;2(3):209–16.

15.

Nucci MR, Drapkin R, Dal Cin P, Fletcher CD, Fletcher JA. Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications. Am J Surg Pathol. 2007;31(5):737–43. https://doi.org/10.1097/01.pas.0000213414.15633.4e.CrossRefPubMed

16.

Anderson LN, Cotterchio M, Knight JA, Borgida A, Gallinger S, Cleary SP. Genetic variants in vitamin d pathway genes and risk of pancreas cancer; results from a population-based case-control study in ontario, Canada. PLoS One. 2013;8(6):e66768. https://doi.org/10.1371/journal.pone.0066768.CrossRefPubMedPubMedCentral

17.

Moon H, Ju HL, Chung SI, Cho KJ, Eun JW, Nam SW, et al. Transforming growth factor beta promotes liver tumorigenesis in mice via upregulation of snail. Gastroenterology. 2017. https://doi.org/10.1053/j.gastro.2017.07.014.CrossRefPubMed

18.

Blevins-Primeau AS, Sun D, Chen G, Sharma AK, Gallagher CJ, Amin S, et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Can Res. 2009;69(5):1892–900. https://doi.org/10.1158/0008-5472.CAN-08-3708.CrossRef

19.

de Haas EC, Zwart N, Meijer C, Nuver J, Boezen HM, Suurmeijer AJ, et al. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(11):1817–23. https://doi.org/10.1200/JCO.2007.14.1606.CrossRef

20.

Makinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334(6053):252–5. https://doi.org/10.1126/science.1208930.CrossRefPubMed

21.

Davies EM, Sheffield DA, Tibarewal P, Fedele CG, Mitchell CA, Leslie NR. The PTEN and Myotubularin phosphoinositide 3-phosphatases: linking lipid signalling to human disease. Sub Cell Biochem. 2012;58:281–336. https://doi.org/10.1007/978-94-007-3012-0_8.CrossRef

22.

Mizuno M, Nawa A, Nakanishi T, Yatabe Y. Clinical benefit of endocrine therapy for benign metastasizing leiomyoma. Int J Clin Oncol. 2011;16(5):587–91. https://doi.org/10.1007/s10147-010-0156-4.CrossRefPubMed

23.

Abramson S, Gilkeson RC, Goldstein JD, Woodard PK, Eisenberg R, Abramson N. Benign metastasizing leiomyoma: clinical, imaging, and pathologic correlation. AJR Am J Roentgenol. 2001;176(6):1409–13. https://doi.org/10.2214/ajr.176.6.1761409.CrossRefPubMed

24.

Lewis EI, Chason RJ, DeCherney AH, Armstrong A, Elkas J, Venkatesan AM. Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review. Fertil Steril. 2013;99(7):2017–24. https://doi.org/10.1016/j.fertnstert.2013.01.147.CrossRefPubMedPubMedCentral

25.

Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, et al. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res BCR. 2014;16(5):430. https://doi.org/10.1186/s13058-014-0430-x.CrossRefPubMed

26.

Ottlakan A, Borda B, Lazar G, Tiszlavicz L, Furak J. Treatment decision based on the biological behavior of pulmonary benign metastasizing leiomyoma. J Thorac Dis. 2016;8(8):E672–6. https://doi.org/10.21037/jtd.2016.06.61.CrossRefPubMedPubMedCentral

Title: Deep sequencing reveals the molecular pathology characteristics between primary uterine leiomyoma and pulmonary benign metastasizing leiomyoma
Authors: J. Jiang
M. He
X. Hu
C. Ni
L. Yang
Publication date: 01-08-2018
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 8/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-018-1847-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2018

Reduction–oxidation (redox) system in radiation-induced normal tissue injury: molecular mechanisms and implications in radiation therapeutics

Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis

Adjuvant concurrent chemoradiation therapy in patients with microscopic residual tumor after curative resection for extrahepatic cholangiocarcinoma

Survey on paediatric tumour boards in Europe: current situation and results from the ExPo-r-Net project

Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

Oncological strategies for locally advanced rectal cancer with synchronous liver metastases, interval strategy versus rectum first strategy: a comparison of short-term outcomes

Keynote webinar | Spotlight on antibody–drug conjugates in cancer